 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 906016
Online Users : 632
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/3847
|
| Title: | Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells |
| Authors: | Tu, SH;Chang, CC;Chen, CS;Tam, KW;Wang, YJ;Lee, CH;Lin, HW;Cheng, TC;Huang, CS;Chu, JS;Shih, NY;Chen, LC;Leu, SJ;Ho, YS;Wu, CH |
| Contributors: | National Institute of Cancer Research |
| Abstract: | Enolase-α (ENO-1) is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers. To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis. Increased ENO-1 mRNA expression was preferentially detected in estrogen receptor-positive (ER+) tumors (tumor/normal ratio >90-fold) when compared to ER-negative (tumor/normal ratio >20-fold) tumor tissues. The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size (>2 cm, *P = .017), poor nodal status (N > 3, *P = .018), and a shorter disease-free interval (≦1 year, *P < .009). We also found that higher-expressing ENO-1 tumors confer longer distance relapse (tumor/normal ratio = 82.8-92.4-fold) when compared to locoregional relapse (tumor/normal ratio = 43.4-fold) in postsurgical 4-hydroxy-tamoxifen (4-OHT)-treated ER+ patients (*P = .014). These data imply that changes in tumor ENO-1 levels are related to clinical 4-OHT therapeutic outcome. In vitro studies demonstrated that decreasing ENO-1 expression using small interfering RNA (siRNA) significantly augmented 4-OHT (100 nM)-induced cytotoxicity in tamoxifen-resistant (Tam-R) breast cancer cells. These results suggest that downregulation of ENO-1 could be utilized as a novel pharmacological approach for overcoming 4-OHT resistance in breast cancer therapy. |
| Date: | 2010-06 |
| Relation: | Breast Cancer Research and Treatment. 2010 Jun;121(3):539-553. |
| Link to: | http://dx.doi.org/10.1007/s10549-009-0492-0 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0167-6806&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000277636000001 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77953122846 |
| Appears in Collections: | [施能耀] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| SCP67949109339.pdf | | 764Kb | Adobe PDF | 806 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
